Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Dementia01:30

Dementia

482
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
482
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

744
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
744
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Imbalance in excitation and inhibition in sgACC is associated with depression in dementia with Lewy bodies.

Translational psychiatry·2026
Same author

Acute and Chronic Effects of High-Load Resistance Training With Blood Flow Restriction in Healthy Adults: A Systematic Review and Meta-Analysis.

Journal of strength and conditioning research·2026
Same author

Laboratory-based turning performance during walking in people with mild cognitive impairment and dementia.

Journal of Alzheimer's disease : JAD·2026
Same author

Peak Oxygen Uptake Provides a Better Predictor of Rowing Ergometer Mean Maximal Power Than Maximal Oxygen Extraction in Trained Rowers.

Journal of strength and conditioning research·2026
Same author

Composite scores to detect and monitor cognitive dysfunction in preclinical and prodromal Alzheimer's disease: A narrative review.

Journal of Alzheimer's disease : JAD·2026
Same author

Delphi consensus guidelines for the use of striatal dopaminergic imaging and cardiac metaiodobenzylguanidine (MIBG) scintigraphy for the diagnosis of dementia and mild cognitive impairment with Lewy bodies.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026

相关实验视频

Updated: Jan 8, 2026

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills
07:31

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills

Published on: February 13, 2020

7.3K

技术与痴呆症 会议前会议

Ríona Mc Ardle1,2, Cameron Kirk3, Silvia Del Din2,4

  • 1NIHR Newcastle Biomedical Research Centre, Newcastle University, Newcastle upon Tyne, Tyne and Wear, UK.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 23, 2025
PubMed
概括
此摘要是机器生成的。

使用加速度计进行现实世界的行走评估对于后皮层缩 (PCA) 是可行的. 与勒维体病 (LBD) 相比,PCA患者表现出不同的行走模式,与阿尔茨海默病 (AD) 有更多相似之处.

更多相关视频

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living
08:36

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living

Published on: July 28, 2022

4.3K
Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

2.0K

相关实验视频

Last Updated: Jan 8, 2026

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills
07:31

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills

Published on: February 13, 2020

7.3K
The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living
08:36

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living

Published on: July 28, 2022

4.3K
Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

2.0K

科学领域:

  • 神经科学是一个神经科学.
  • 老年学是一门学科.
  • 生物医学工程 生物医学工程

背景情况:

  • 后皮层缩 (PCA) 是一种痴呆症亚型,由于异常症状和临床意识低,经常被误诊.
  • 基于加速度计的步态分析在区分Lewy体疾病 (LBD) 和阿尔茨海默氏病 (AD) 中表现出有希望.
  • 现实世界行走评估提供了关于神经退行性疾病日常功能影响的见解.

研究的目的:

  • 评估基于加速度计的真实世界行走评估在PCA患者中的可行性.
  • 为了确定PCA,AD和LBD之间的现实世界行走特征的差异.

主要方法:

  • 14名患有PCA的参与者在长达7天的时间内佩戴加速度计,以收集真实世界的行走数据.
  • 经过验证的算法获得了步行结果,包括质量,体积,模式和可变性.
  • 将PCA数据与AD和LBD队列的现有数据进行了比较.

主要成果:

  • 对于所有PCA参与者来说,在推的持续时间内,对现实世界的行走评估是可行的.
  • 与LBD组相比,PCA参与者表现出明显更快的步行速度,更大的步行量 (每天的分钟,步骤,发作) (p <0.01).
  • 在PCA和LBD之间没有发现步行模式或变异性的显著差异,PCA和AD之间也没有显著差异.

结论:

  • 基于加速度计的现实世界行走评估是研究PCA的一种可行的方法.
  • 初步发现表明,PCA的宏观行走行为与AD的行为更类似,而不是LBD.
  • 进一步的研究将探索PCA中的微步特征,以提高诊断差异化.